SPECTRUM: HER2 expression in endometrial cancer
Presented by Prof Christine Gennigens (University Hospital de Liège, Belgium)
This poster presents findings from the Spectrum study, a single-center retrospective analysis of endometrial cancer cases between 2003 and 2019, utilising available tissue samples. The study aimed to determine the rate of HER2 low expression (1+ and 2+), assess the concordance between breast and endometrial criteria for HER2, and evaluate the impact of HER2 low expression on survival outcomes.
The study included 193 patients, primarily with stage 1 cancer. About 60% were classified as low-grade endometrioid, with 14% being serous. The molecular categorisation revealed 3% POLE, 25% MMRd, 28% TP53, and the remaining in the non-molecular-specific group.
The first objective focused on HER2 expression rates. Most of the population showed no HER2 expression, while about 30% had low (26%) or high (4%) HER2 expression. The highest rates of HER2 low expression were observed in the POLE and TP53 abnormal populations.
The second objective examined the concordance between breast and endometrial criteria for HER2, revealing an 85% agreement.
The third objective assessed the prognostic impact of HER2 expression on survival outcomes, concluding that HER2 expression did not significantly affect survival.
This information is valuable as new drugs targeting HER2 expression are emerging in the treatment landscape for endometrial cancer.
References:
Cortes A. et al., ASCO2024 #abstract 5610
